Huguet I, Grossman AB, O'Toole D. Changes in the epidemiology of neuroendocrine Tumours. Neuroendocrinology. 2017;104(2):105–11.
CAS
PubMed
Google Scholar
Pavel M, de Herder WW. ENETS consensus guidelines for the standard of Care in Neuroendocrine Tumors. Neuroendocrinology. 2017;105(3):193–5.
CAS
PubMed
Google Scholar
Auernhammer CJ, Spitzweg C, Bock S, Knosel T, Bartenstein P. Current standards and novel developments in the treatment of neuroendocrine tumors of the gastroenteropancreatic system. Dtsch Med Wochenschr. 2019;144(20):1390–5.
CAS
PubMed
Google Scholar
Grillo F, Florio T, Ferrau F, Kara E, Fanciulli G, Faggiano A, Colao A, Group N. Emerging multitarget tyrosine kinase inhibitors in the treatment of neuroendocrine neoplasms. Endocr Relat Cancer. 2018;25(9):R453–66.
PubMed
Google Scholar
Jin XF, Auernhammer CJ, Ilhan H, Lindner S, Nolting S, Maurer J, Spottl G, Orth M. Combination of 5-fluorouracil with epigenetic modifiers induces Radiosensitization, Somatostatin receptor 2 expression, and Radioligand binding in neuroendocrine tumor cells in vitro. J Nucl Med. 2019;60(9):1240–6.
CAS
PubMed
Google Scholar
Aristizabal Prada ET, Auernhammer CJ. Targeted therapy of gastroenteropancreatic neuroendocrine tumours: preclinical strategies and future targets. Endocr Connect. 2018;7(1):R1–R25.
CAS
PubMed
Google Scholar
Kloker LD, Berchtold S, Smirnow I, Schaller M, Fehrenbacher B, Krieg A, Sipos B, Lauer UM. The Oncolytic Herpes Simplex Virus Talimogene Laherparepvec shows promising efficacy in neuroendocrine cancer cell lines. Neuroendocrinology. 2019;109(4):346–61.
CAS
PubMed
Google Scholar
Essand M. Virotherapy of neuroendocrine tumors. Neuroendocrinology. 2013;97(1):26–34.
CAS
PubMed
Google Scholar
Yu D, Leja-Jarblad J, Loskog A, Hellman P, Giandomenico V, Oberg K, Essand M. Preclinical evaluation of AdVince, an Oncolytic adenovirus adapted for treatment of liver metastases from neuroendocrine Cancer. Neuroendocrinology. 2017;105(1):54–66.
CAS
PubMed
Google Scholar
Rudin CM, Poirier JT, Senzer NN, Stephenson J Jr, Loesch D, Burroughs KD, Reddy PS, Hann CL, Hallenbeck PL. Phase I clinical study of Seneca Valley virus (SVV-001), a replication-competent picornavirus, in advanced solid tumors with neuroendocrine features. Clin Cancer Res. 2011;17(4):888–95.
CAS
PubMed
PubMed Central
Google Scholar
Zhang Q, Yu YA, Wang E, Chen N, Danner RL, Munson PJ, Marincola FM, Szalay AA. Eradication of solid human breast tumors in nude mice with an intravenously injected light-emitting oncolytic vaccinia virus. Cancer Res. 2007;67(20):10038–46.
CAS
PubMed
Google Scholar
Zhang Q, Liang C, Yu YA, Chen N, Dandekar T, Szalay AA. The highly attenuated oncolytic recombinant vaccinia virus GLV-1h68: comparative genomic features and the contribution of F14.5L inactivation. Mol Gen Genomics. 2009;282(4):417–35.
CAS
Google Scholar
Lauer UM, Schell M, Beil J, Berchtold S, Koppenhofer U, Glatzle J, Konigsrainer A, Mohle R, Nann D, Fend F, et al. Phase I study of oncolytic vaccinia virus GL-ONC1 in patients with peritoneal carcinomatosis. Clin Cancer Res. 2018;24(18):4388–98.
CAS
PubMed
Google Scholar
Mell LK, Brumund KT, Daniels GA, Advani SJ, Zakeri K, Wright ME, Onyeama SJ, Weisman RA, Sanghvi PR, Martin PJ, et al. Phase I trial of intravenous Oncolytic Vaccinia virus (GL-ONC1) with Cisplatin and radiotherapy in patients with Locoregionally advanced Head and neck carcinoma. Clin Cancer Res. 2017;23(19):5696–702.
CAS
PubMed
Google Scholar
Lin SF, Price DL, Chen CH, Brader P, Li S, Gonzalez L, Zhang Q, Yu YA, Chen N, Szalay AA, et al. Oncolytic vaccinia virotherapy of anaplastic thyroid cancer in vivo. J Clin Endocrinol Metab. 2008;93(11):4403–7.
CAS
PubMed
PubMed Central
Google Scholar
Pugalenthi A, Mojica K, Ady JW, Johnsen C, Love D, Chen NG, Aguilar RJ, Szalay AA, Fong Y. Recombinant vaccinia virus GLV-1h68 is a promising oncolytic vector in the treatment of cholangiocarcinoma. Cancer Gene Ther. 2015;22(12):591–6.
CAS
PubMed
Google Scholar
Hofmann E, Weibel S, Szalay AA. Combination treatment with oncolytic Vaccinia virus and cyclophosphamide results in synergistic antitumor effects in human lung adenocarcinoma bearing mice. J Transl Med. 2014;12:197.
PubMed
PubMed Central
Google Scholar
Wilkinson MJ, Smith HG, Pencavel TD, Mansfield DC, Kyula-Currie J, Khan AA, McEntee G, Roulstone V, Hayes AJ, Harrington KJ. Isolated limb perfusion with biochemotherapy and oncolytic virotherapy combines with radiotherapy and surgery to overcome treatment resistance in an animal model of extremity soft tissue sarcoma. Int J Cancer. 2016;139(6):1414–22.
CAS
PubMed
PubMed Central
Google Scholar
Kyula JN, Khan AA, Mansfield D, Karapanagiotou EM, McLaughlin M, Roulstone V, Zaidi S, Pencavel T, Touchefeu Y, Seth R, et al. Synergistic cytotoxicity of radiation and oncolytic Lister strain vaccinia in (V600D/E) BRAF mutant melanoma depends on JNK and TNF-alpha signaling. Oncogene. 2014;33(13):1700–12.
CAS
PubMed
Google Scholar
Binz E, Berchtold S, Beil J, Schell M, Geisler C, Smirnow I, Lauer UM. Chemovirotherapy of pancreatic adenocarcinoma by combining Oncolytic Vaccinia virus GLV-1h68 with nab-paclitaxel plus gemcitabine. Mol Ther Oncolytics. 2017;6:10–21.
CAS
PubMed
PubMed Central
Google Scholar
Advani SJ, Buckel L, Chen NG, Scanderbeg DJ, Geissinger U, Zhang Q, Yu YA, Aguilar RJ, Mundt AJ, Szalay AA. Preferential replication of systemically delivered oncolytic vaccinia virus in focally irradiated glioma xenografts. Clin Cancer Res. 2012;18(9):2579–90.
PubMed
Google Scholar
Evgin L, Acuna SA, Tanese de Souza C, Marguerie M, Lemay CG, Ilkow CS, Findlay CS, Falls T, Parato KA, Hanwell D, et al. Complement inhibition prevents oncolytic vaccinia virus neutralization in immune humans and cynomolgus macaques. Mol Ther. 2015;23(6):1066–76.
CAS
PubMed
PubMed Central
Google Scholar
Kim J, Hall RR, Lesniak MS, Ahmed AU. Stem cell-based cell carrier for targeted Oncolytic Virotherapy: translational opportunity and open questions. Viruses. 2015;7(12):6200–17.
CAS
PubMed
PubMed Central
Google Scholar
Minev BR, Lander E, Feller JF, Berman M, Greenwood BM, Minev I, Santidrian AF, Nguyen D, Draganov D, Killinc MO, et al. First-in-human study of TK-positive oncolytic vaccinia virus delivered by adipose stromal vascular fraction cells. J Transl Med. 2019;17(1):271.
PubMed
PubMed Central
Google Scholar
Daskalakis K, Tsoli M, Angelousi A, Kassi E, Alexandraki K, Kolomodi D, Kaltsas G, Koumarianou A. Anti-tumour activity of everolimus and sunitinib in neuroendocrine neoplasms. Endocr Connect. 2019;8(6):641–53.
CAS
PubMed
PubMed Central
Google Scholar
Yoo C, Cho H, Song MJ, Hong SM, Kim KP, Chang HM, Chae H, Kim TW, Hong YS, Ryu MH, et al. Efficacy and safety of everolimus and sunitinib in patients with gastroenteropancreatic neuroendocrine tumor. Cancer Chemother Pharmacol. 2017;79(1):139–46.
CAS
PubMed
Google Scholar
Angelousi A, Kamp K, Kaltsatou M, O'Toole D, Kaltsas G, de Herder W. Sequential Everolimus and Sunitinib treatment in pancreatic metastatic well-differentiated neuroendocrine Tumours resistant to prior treatments. Neuroendocrinology. 2017;105(4):394–402.
CAS
PubMed
Google Scholar
Takahashi T, Nau MM, Chiba I, Birrer MJ, Rosenberg RK, Vinocour M, Levitt M, Pass H, Gazdar AF, Minna JD. p53: a frequent target for genetic abnormalities in lung cancer. Science. 1989;246(4929):491–4.
CAS
PubMed
Google Scholar
Giaccone G, Battey J, Gazdar AF, Oie H, Draoui M, Moody TW. Neuromedin B is present in lung cancer cell lines. Cancer Res. 1992;52(9 Suppl):2732s–6s.
CAS
PubMed
Google Scholar
Evers BM, Ishizuka J, Townsend CM Jr, Thompson JC. The human carcinoid cell line, BON. A model system for the study of carcinoid tumors. Ann N Y Acad Sci. 1994;733:393–406.
CAS
PubMed
Google Scholar
Kaku M, Nishiyama T, Yagawa K, Abe M. Establishment of a carcinoembryonic antigen-producing cell line from human pancreatic carcinoma. Gan. 1980;71(5):596–601.
CAS
PubMed
Google Scholar
Linnebacher M, Maletzki C, Ostwald C, Klier U, Krohn M, Klar E, Prall F. Cryopreservation of human colorectal carcinomas prior to xenografting. BMC Cancer. 2010;10:362.
PubMed
PubMed Central
Google Scholar
Krieg A, Mersch S, Boeck I, Dizdar L, Weihe E, Hilal Z, Krausch M, Mohlendick B, Topp SA, Piekorz RP, et al. New model for gastroenteropancreatic large-cell neuroendocrine carcinoma: establishment of two clinically relevant cell lines. PLoS One. 2014;9(2):e88713.
PubMed
PubMed Central
Google Scholar
Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, Boyd MR. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst. 1990;82(13):1107–12.
CAS
PubMed
Google Scholar
Xing JZ, Zhu L, Jackson JA, Gabos S, Sun XJ, Wang XB, Xu X. Dynamic monitoring of cytotoxicity on microelectronic sensors. Chem Res Toxicol. 2005;18(2):154–61.
CAS
PubMed
Google Scholar
Kirn DH, Thorne SH. Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer. Nat Rev Cancer. 2009;9(1):64–71.
CAS
PubMed
Google Scholar
Tolonen N, Doglio L, Schleich S, Krijnse LJ. Vaccinia virus DNA replication occurs in endoplasmic reticulum-enclosed cytoplasmic mini-nuclei. Mol Biol Cell. 2001;12(7):2031–46.
CAS
PubMed
PubMed Central
Google Scholar
Walsh SR, Dolin R. Vaccinia viruses: vaccines against smallpox and vectors against infectious diseases and tumors. Expert Rev Vaccines. 2011;10(8):1221–40.
CAS
PubMed
PubMed Central
Google Scholar
Worschech A, Chen N, Yu YA, Zhang Q, Pos Z, Weibel S, Raab V, Sabatino M, Monaco A, Liu H, et al. Systemic treatment of xenografts with vaccinia virus GLV-1h68 reveals the immunologic facet of oncolytic therapy. BMC Genomics. 2009;10:301.
PubMed
PubMed Central
Google Scholar
Mastrangelo MJ, Maguire HC Jr, Eisenlohr LC, Laughlin CE, Monken CE, McCue PA, Kovatich AJ, Lattime EC. Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma. Cancer Gene Ther. 1999;6(5):409–22.
CAS
PubMed
Google Scholar
Tsoneva D, Minev B, Frentzen A, Zhang Q, Wege AK, Szalay AA. Humanized mice with subcutaneous human solid tumors for immune response analysis of Vaccinia virus-mediated Oncolysis. Mol Ther Oncolytics. 2017;5:41–61.
CAS
PubMed
PubMed Central
Google Scholar
Smith HG, Mansfield D, Roulstone V, Kyula-Currie JN, McLaughlin M, Patel RR, Bergerhoff KF, Paget JT, Dillon MT, Khan A, et al. PD-1 blockade following isolated limb perfusion with Vaccinia virus prevents local and distant relapse of soft-tissue sarcoma. Clin Cancer Res. 2019;25(11):3443–54.
PubMed
Google Scholar
Tappe KA, Budida R, Stankov MV, Frenz T, Shah HR, Volz A, Sutter G, Kalinke U, GMN B. Immunogenic cell death of dendritic cells following modified vaccinia virus Ankara infection enhances CD8(+) T cell proliferation. Eur J Immunol. 2018;48(12):2042–54.
CAS
PubMed
Google Scholar
Ehrig K, Kilinc MO, Chen NG, Stritzker J, Buckel L, Zhang Q, Szalay AA. Growth inhibition of different human colorectal cancer xenografts after a single intravenous injection of oncolytic vaccinia virus GLV-1h68. J Transl Med. 2013;11:79.
CAS
PubMed
PubMed Central
Google Scholar
Ma XM, Blenis J. Molecular mechanisms of mTOR-mediated translational control. Nat Rev Mol Cell Biol. 2009;10(5):307–18.
Google Scholar
Lun XQ, Jang JH, Tang N, Deng H, Head R, Bell JC, Stojdl DF, Nutt CL, Senger DL, Forsyth PA, et al. Efficacy of systemically administered oncolytic vaccinia virotherapy for malignant gliomas is enhanced by combination therapy with rapamycin or cyclophosphamide. Clin Cancer Res. 2009;15(8):2777–88.
CAS
PubMed
Google Scholar
Lun X, Chan J, Zhou H, Sun B, Kelly JJ, Stechishin OO, Bell JC, Parato K, Hu K, Vaillant D, et al. Efficacy and safety/toxicity study of recombinant vaccinia virus JX-594 in two immunocompetent animal models of glioma. Mol Ther. 2010;18(11):1927–36.
CAS
PubMed
PubMed Central
Google Scholar
Kim M, Nitschke M, Sennino B, Murer P, Schriver BJ, Bell A, Subramanian A, McDonald CE, Wang J, Cha H, et al. Amplification of Oncolytic Vaccinia virus widespread tumor cell killing by Sunitinib through multiple mechanisms. Cancer Res. 2018;78(4):922–37.
CAS
PubMed
Google Scholar
Yu YA, Galanis C, Woo Y, Chen N, Zhang Q, Fong Y, Szalay AA. Regression of human pancreatic tumor xenografts in mice after a single systemic injection of recombinant vaccinia virus GLV-1h68. Mol Cancer Ther. 2009;8(1):141–51.
CAS
PubMed
PubMed Central
Google Scholar
Malfitano AM, Di Somma S, Iannuzzi CA, Pentimalli F, Portella G. Virotherapy: from single agents to combinatorial treatments. Biochem Pharmacol. 2020;177:113986.
CAS
PubMed
Google Scholar
Heise C, Lemmon M, Kirn D. Efficacy with a replication-selective adenovirus plus cisplatin-based chemotherapy: dependence on sequencing but not p53 functional status or route of administration. Clin Cancer Res. 2000;6(12):4908–14.
CAS
PubMed
Google Scholar
Binz E, Lauer UM. Chemovirotherapy: combining chemotherapeutic treatment with oncolytic virotherapy. Oncolytic Virother. 2015;4:39–48.
CAS
PubMed
PubMed Central
Google Scholar